% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Eichkorn:166486,
      author       = {T. Eichkorn and F. Bozorgmehr and S. Regnery and L. A.
                      Dinges and A. Kudak$^*$ and N. Bougatf$^*$ and D. Weber and
                      P. Christopoulos and T. Muley and S. Kobinger and L. König
                      and J. Hörner-Rieber$^*$ and S. Adeberg and C. P. Heussel
                      and M. Thomas and J. Debus$^*$ and R. A. El Shafie},
      title        = {{C}onsolidation {I}mmunotherapy {A}fter {P}latinum-{B}ased
                      {C}hemoradiotherapy in {P}atients {W}ith {U}nresectable
                      {S}tage {III} {N}on-{S}mall {C}ell {L}ung
                      {C}ancer-{C}ross-{S}ectional {S}tudy of {E}ligibility and
                      {A}dministration {R}ates.},
      journal      = {Frontiers in oncology},
      volume       = {10},
      issn         = {2234-943X},
      address      = {Lausanne},
      publisher    = {Frontiers Media},
      reportid     = {DKFZ-2020-02929},
      pages        = {586449},
      year         = {2020},
      abstract     = {The PACIFC trial demonstrated a significant benefit of
                      durvalumab consolidation immunotherapy (CIT) after
                      definitive platinum-based chemoradiotherapy (P-CRT) for
                      survival in stage III non-small cell lung cancer (NSCLC). It
                      is unknown how many patients are eligible in clinical
                      practice to receive CIT according to PACIFIC criteria
                      compared to real administration rates and what influencing
                      factors are.We analyzed 442 patients with unresectable stage
                      III NSCLC who received P-CRT between 2009 and 2019 regarding
                      CIT eligibility rates according to PACIFIC criteria and
                      administration rates since drug approval.Sixty-four percent
                      of 437 patients were male, median age was 63 years
                      [interquartile range (IQR): 57-69]. The most common
                      histologic subtypes were adenocarcinoma $(42.8\%)$ and
                      squamous cell carcinoma $(41.1\%),$ most tumors were in
                      stage IIIB $(56.8\%).$ Mean PD-L1 tumor proportion score
                      (TPS) was $29.8\%$ (IQR: 1-60). The median total RT dose was
                      60 Gy (IQR: 60-66). Platinum component of P-CRT was evenly
                      distributed between cisplatin $(51.4\%)$ and carboplatin
                      $(48.6\%).$ $50.3\%$ of patients were eligible for CIT
                      according to PACIFIC criteria. Observed contraindications
                      were progressive disease according to RECIST $(32.4\%),$
                      followed by a PD-L1 TPS < $1\%$ $(22.3\%),$ pneumonitis
                      CTCAE ≥ 2 $(12.6\%)$ and others $(4.9\%).$ One year after
                      drug approval, $85.6\%$ of patients who were eligible
                      according to PACIFIC criteria actually received CIT. Time
                      interval between chemotherapy start and radiation therapy
                      start (OR 0.9, $95\%$ CI: [0.9; 1.0] p = 0.009) and probably
                      cisplatin as platinum-component of P-CRT (OR 1.5, $95\%$ CI:
                      [1.0; 2.4] p < 0.061) influence CIT eligibility. Highly
                      positive PD-L1 TPS $(≥50\%;$ (OR 2.4, $95\%$ CI: [1.3;
                      4.5] p = 0.004) was associated to a better chance for CIT
                      eligibility.Eighty-five percent of potentially eligible
                      patients received CIT one year after drug approval. Fifty
                      percent of patients did not meet PACIFIC criteria for
                      durvalumab eligibility, this was mainly caused by disease
                      progression during platinum-based CRT, followed by
                      therapy-related pneumonitis and PD-L1 TPS < $1\%$ (in view
                      of the EMA drug approval).},
      keywords     = {PACIFIC criteria (Other) / definitive platinum-based
                      chemoradiotherapy (Other) / durvalumab admission rate
                      (Other) / durvalumab eligibility rate (Other) / non-small
                      cell lung cancer stage III (Other)},
      cin          = {E050 / HD01},
      ddc          = {610},
      cid          = {I:(DE-He78)E050-20160331 / I:(DE-He78)HD01-20160331},
      pnm          = {315 - Imaging and radiooncology (POF3-315)},
      pid          = {G:(DE-HGF)POF3-315},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:33335856},
      pmc          = {pmc:PMC7736629},
      doi          = {10.3389/fonc.2020.586449},
      url          = {https://inrepo02.dkfz.de/record/166486},
}